Maryalice Stetler-Stevenson

List of Publications by Year
in descending order

128 papers	7,696 citations	94381 37 h-index	54882 84 g-index
130 all docs	130 docs citations	130 times ranked	8945 citing authors

#	Article	IF	Citations
1	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 2018, 24, 20-28.	15.2	1,030
2	The lymph node microenvironment promotes B-cell receptor signaling, NF-Î²B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood, 2011, 117, 563-574.	0.6	746
3	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. Journal of Clinical Oncology, 2000, 18, 1622-1636.	0.8	416
4	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 169-176.	5.1	344
5	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood, 2017, 129, 1469-1479.	0.6	276
6	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. Journal of Clinical Oncology, 2020, 38, 1938-1950.	0.8	273
7	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	3.4	266
8	Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood, 2015, 126, 2213-2219.	0.6	198
9	Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. Molecular Therapy - Oncolytics, 2018, 11, 127-137.	2.0	191
10	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. Journal of Clinical Oncology, 2021, 39, 1650-1659.	0.8	173
11	Doublet discrimination in DNA cell-cycle analysis. Cytometry, 2001, 46, 296-306.	1.8	168
12	Disruption of in vivo Chronic Lymphocytic Leukemia Tumorâ€“Microenvironment Interactions by Ibrutinib â€“ Findings from an Investigator-Initiated Phase II Study. Clinical Cancer Research, 2016, 22, 1572-1582.	3.2	168
13	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood, 2018, 131, 2357-2366.	0.6	166
14	Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor VÎ² profiles. British Journal of Haematology, 1998, 102, 1314-1322.	1.2	152
15	Tissue Inhibitor of Metalloproteinase (TIMP)-1 Induces Differentiation and an Antiapoptotic Phenotype in Germinal Center B Cells. Blood, 1998, 92, 1342-1349.	0.6	142
16	Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica, 2018, 103, e215-e218.	1.7	131
17	Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence. Clinical Cancer Research, 2019, 25, 5329-5341.	3.2	130
18	U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation. , 1997, 30, 236-244.		116

#	Article	IF	Citations
19	A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica, 2014, 99, e81-e83.	1.7	112
20	Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry Part B - Clinical Cytometry, 2016, 90, 26-30.	0.7	108
21	Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. British Journal of Haematology, 2001, 112, 195-200.	1.2	107
22	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia, 2017, 31, 1340-1347.	3.3	103
23	Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leukemia Research, 2013, 37, 401-409.	0.4	100
24	Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature Reviews Clinical Oncology, 2015, 12, 286-295.	12.5	97
25	Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene, 1997, 15, 107-115.	2.6	93
26	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. Journal of Clinical Oncology, 2022, 40, 932-944.	0.8	93
27	Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood, 2021, 138, 2469-2484.	0.6	79
28	Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research, 2014, 38, 371-376.	0.4	76
29	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. Clinical Cancer Research, 2016, 22, 86-95.	3.2	75
30	Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Advances, 2019, 3, 2317-2322.	2.5	69
31	Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood, 2020, 136, 93-105.	0.6	68
32	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood, 2018, 131, 2331-2334.	0.6	64
33	The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene upâ€regulation in rat la fibroblasts. FASEB Journal, 1997, 11, 965-972.	0.2	63
34	Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. , 1996, 26, 243-252.		60
35	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clinical Immunology, 2014, 155, 176-187.	1.4	60
36	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2020, 38, 1527-1538.	0.8	58

#	Article	IF	Citations
37	Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood, 2017, 130, 1620-1627.	0.6	57
38	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. Clinical Cancer Research, 2016, 22, 310-318.	3.2	48
39	bcl-2 Expression in Hodgkinâ€™s Disease: Correlation with the t(14; 18) Translocation and Epstein-Barr Virus. American Journal of Clinical Pathology, 1993, 99, 604-608.	0.4	40
40	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clinical Cancer Research, 2018, 24, 2859-2872.	3.2	40
41	Increased peripheral blood gamma delta T-cells in patients with lymphoid neoplasia: A diagnostic dilemma in flow cytometry. Cytometry, 1999, 38, 280-285.	1.8	35
42	Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 684-684.	0.6	35
43	Tissue Inhibitor of Metalloproteinase-2 Induces Apoptosis in Human T Lymphocytes. Annals of the New York Academy of Sciences, 1999, 878, 522-523.	1.8	34
44	Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 650-650.	0.6	34
45	Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leukemia Research, 2018, 71, 106-111.	0.4	33
46	Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. Leukemia, 2020, 34, 3064-3069.	3.3	33
47	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1â€“Associated Adult T-cell Leukemia/lymphoma. Clinical Cancer Research, 2017, 23, 35-42.	3.2	31
48	Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2013, 122, 538-538.	0.6	30
49	Diagnosis of hairy cell leukemia by flow cytometry. Leukemia and Lymphoma, 2011, 52, 11-13.	0.6	27
50	Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies. Current Protocols in Cytometry, 2018, 86, e44.	3.7	27
51	Flow cytometry in lymphoma diagnosis and prognosis: useful?. Best Practice and Research in Clinical Haematology, 2003, 16, 583-597.	0.7	26
52	2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia. Cytometry Part B - Clinical Cytometry, 2007, 72B, S3-S3.	0.7	25
53	Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. Breast Cancer Research and Treatment, 2000, 59, 27-39.	1.1	24
54	T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma. Blood, 2019, 134, 3230-3230.	0.6	24

#	Article	IF	Citations
55	Debris compensation of Dna histograms and its effect on S-phase analysis. Cytometry, 1995, 20, 43-52.	1.8	23
56	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. Journal of Immunology, 2018, 201, 1967-1974.	0.4	22
57	Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma. Blood, 2015, 126, 472-472.	0.6	22
58	Artifactual staining of monoclonal antibodies in two-color combinations is due to an immunoglobulin in the serum and plasma. Cytometry, 1994, 18, 140-146.	1.8	21
59	Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. JAMA Oncology, 2021, 7, 132.	3.4	21
60	Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1324-1324.	0.6	21
61	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. , 2022, 10, e004483.		21
62	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 275-282.	0.7	20
63	Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor. Blood, 2015, 126, LBA-1-LBA-1.	0.6	20
64	Development of Lymphoproliferative Disorder of Granular Lymphocytes in Association with Hairy Cell Leukemia. Leukemia and Lymphoma, 2000, 37, 97-104.	0.6	19
65	Genotypic Analysis of Diffuse, Mixed Cell Lymphomas: Comparisons with Morphologic and Immunophenotypic Findings. American Journal of Clinical Pathology, 1991, 95, 547-555.	0.4	18
66	Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. American Journal of Hematology, 2016, 91, E502-E503.	2.0	18
67	Early recovery of circulating immature B cells in Bâ€lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection. Cytometry Part B - Clinical Cytometry, 2018, 94, 434-443.	0.7	14
68	Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. Blood, 2020, 136, 50-51.	0.6	14
69	Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. Bone Marrow Transplantation, 2018, 53, 1445-1449.	1.3	12
70	Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow. American Journal of Clinical Pathology, 2020, 153, 322-327.	0.4	12
71	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. JAMA Oncology, 2021, 7, 1678.	3.4	12
72	A Pilot Trial of Campath-1H and Dose-Adjusted EPOCH in CD52-Expressing Aggressive T-Cell Malignancies.. Blood, 2005, 106, 3348-3348.	0.6	12

#	Article	IF	Citations
73	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma, 2017, 58, 639-645.	0.6	11
74	Disease detection methodologies in relapsed Bâ€cell acute lymphoblastic leukemia: Opportunities for improvement. Pediatric Blood and Cancer, 2020, 67, e28149.	0.8	11
75	Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia. Methods in Molecular Biology, 2019, 2032, 311-321.	0.4	11
76	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. Oncologist, 2021, 26, 288-e541.	1.9	10
77	Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains. Blood, 2018, 132, 963-963.	0.6	10
78	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. Blood, 2020, 136, 43-45.	0.6	10
79	KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy. Blood, 2021, 138, 256-256.	0.6	10
80	Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response. Blood, 2018, 132, 282-282.	0.6	9
81	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood, 2021, 138, 3837-3837.	0.6	8
82	Case report: Impact of<scp>BITE</scp>on<scp>CAR</scp>â€T cell expansion. Advances in Cell and Gene Therapy, 2019, 2, e50.	0.6	7
83	Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 839-839.	0.6	7
84	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.. Blood, 2009, 114, 888-888.	0.6	7
85	Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. Aids, 2021, 35, 53-62.	1.0	6
86	Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p. Blood, 2015, 126, 2937-2937.	0.6	6
87	Tissue Inhibitor of Metalloproteinase (TIMP)-1 Induces Differentiation and an Antiapoptotic Phenotype in Germinal Center B Cells. Blood, 1998, 92, 1342-1349.	0.6	6
88	Expression of the muscle-associated gene MYF6 in hairy cell leukemia. PLoS ONE, 2020, 15, e0227586.	1.1	5
89	In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity. Blood, 2013, 122, 4182-4182.	0.6	5
90	Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. Journal of Clinical Oncology, 2019, 37, 7003-7003.	0.8	5

#	Article	IF	Citations
91	Report of the results of the International Clinical Cytometry Society and American Society for Clinical Pathology workload survey of clinical flow cytometry laboratories. Cytometry Part B - Clinical Cytometry, 2017, 92, 525-533.	0.7	4
92	EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.. Blood, 2007, 110, 3565-3565.	0.6	4
93	Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Blood, 2013, 122, 2871-2871.	0.6	4
94	Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study. Blood, 2016, 128, 4527-4527.	0.6	4
95	Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2012, 30, e18568-e18568.	0.8	4
96	Quantitative fluorescence: To count or not to count. Is that the question?. Cytometry, 1998, 34, 203-204.	1.8	3
97	Diagnosis of unexpected acute myeloid leukemia and chronic lymphocytic leukemia: A case report demonstrating the perils of restricted panels in flow cytometric immunophenotyping. , 2000, 42, 114-117.		3
98	Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Haematologica, 2015, 100, e21-e24.	1.7	3
99	A phase <scp>II</scp> study of ibrutinib and shortâ€course fludarabine in previously untreated patients with chronic lymphocytic leukemia. American Journal of Hematology, 2020, 95, E310-E313.	2.0	3
100	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. Blood, 2015, 126, 4161-4161.	0.6	3
101	Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV. Blood, 2019, 134, 4096-4096.	0.6	3
102	Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142). Blood, 2020, 136, 8-9.	0.6	3
103	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leukemia and Lymphoma, 2018, 59, 178-186.	0.6	2
104	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. Blood, 2018, 132, 1957-1957.	0.6	2
105	<scp>ICCS</scp> Women in Cytometryâ€”Impact 10â€‰years later: A call to promote gender equity. Cytometry Part B - Clinical Cytometry, 2021, 100, 282-284.	0.7	1
106	Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing. Blood, 2018, 132, 1861-1861.	0.6	1
107	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. Blood, 2019, 134, 1536-1536.	0.6	1
108	Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).. Blood, 2007, 110, 855-855.	0.6	1

#	Article	IF	Citations
109	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.. Blood, 2008, 112, 2010-2010.	0.6	1
110	Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.. Blood, 2009, 114, 3442-3442.	0.6	1
111	Hevyliteâ„¢ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study. Blood, 2011, 118, 5065-5065.	0.6	1
112	Plasma Circulating Proteasomes As Biomarkers Along Natural History Of Asymptomatic Monoclonal Gammopathies. Blood, 2013, 122, 3133-3133.	0.6	1
113	Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL). Blood, 2015, 126, 1750-1750.	0.6	1
114	Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study. Blood, 2016, 128, 3339-3339.	0.6	1
115	Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate. Blood, 2018, 132, 2963-2963.	0.6	1
116	Dual antibody immunohistochemistry: an efficient and sensitive tool for the detection of residual disease in chronic lymphocytic leukemia. Journal of Hematopathology, 2019, 12, 183-190.	0.2	0
117	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naÃ¯ve chronic lymphocytic leukemia: a phase 2 study. Leukemia and Lymphoma, 2021, 62, 1816-1827.	0.6	0
118	Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. Leukemia and Lymphoma, 2021, 62, 1828-1839.	0.6	0
119	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. Journal of Clinical Oncology, 2021, 39, 7036-7036.	0.8	0
120	Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. Journal of Clinical Oncology, 2012, 30, 2503-2503.	0.8	0
121	A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM).. Journal of Clinical Oncology, 2012, 30, 8088-8088.	0.8	0
122	Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL).. Journal of Clinical Oncology, 2012, 30, 8051-8051.	0.8	0
123	Biologic variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: Multiple biopsies in the same patient.. Journal of Clinical Oncology, 2013, 31, e19506-e19506.	0.8	0
124	Autologous-collected anti-CD19 chimeric antigen receptor T cells (19CARTs) for pediatric acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL): Clinical activity and cytokine release without graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).. Journal of Clinical Oncology, 2013, 31, 10008-10008.	0.8	0
125	Immunophenotypic profiles of plasma cells and tumor burden in patients with smoldering myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS).. Journal of Clinical Oncology, 2014, 32, e19589-e19589.	0.8	0
126	Longitudinal 18f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R). Blood, 2016, 128, 3274-3274.	0.6	0

#	Article	IF	Citations
127	The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases. Blood, 2018, 132, 4859-4859.	0.6	0
128	Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-NaÃ¯ve CLL: A Phase II Study. Blood, 2019, 134, 5474-5474.	0.6	0